Lyle Small: From Color-Changing Cans to Targeted Cancer Therapy
Unable to add items
Add to basket failed.
Add to wishlist failed.
Failed to remove from Wish List.
Adding to library failed
Unable to follow podcast
Unable to unfollow podcast
-
Narrated by:
-
By:
How does the inventor behind the color-changing Coors Light can end up building a new approach to cancer treatment?
In this episode of Entrepreneur Rx, host John Shufeldt sits down with Lyle Small, Founder and CEO of Lahjavida Bio, to talk about a career built around chemistry, persistence, and solving problems other people thought were too difficult.
Lyle is a Cornell-trained bioengineer and longtime inventor who founded Chromatic Technologies, Inc., where he spent decades developing interactive inks and coatings. One of his best-known inventions became the cold-activated technology behind the mountains that turn blue on Coors Light cans.
But that work eventually led him somewhere entirely different.
After hiring a chemist who had worked with a dye that selectively accumulates in cancer cells, Lyle began asking a new question: if the dye could find a tumor, could it carry a treatment with it?
That question became the foundation for Lahjavida Bio.
The company is developing Dye-Drug Conjugates, or DDCs, synthetic small molecules that combine a tumor-seeking near-infrared dye, a cleavable linker, and a cytotoxic payload. The concept borrows from antibody-drug conjugates, but replaces the antibody with a small-molecule dye. The goal is to carry powerful cancer drugs more selectively into tumors while keeping the payload inactive during circulation and releasing it once inside the cancer cell.
Lahjavida’s lead compound, DDC6, pairs its dye platform with MMAE, a payload already used in several approved antibody-drug conjugates. Early preclinical studies have shown tumor growth inhibition, while DDC6 has also appeared less toxic than the unprotected chemotherapy payload in the models studied to date. The company is now working to confirm those findings across additional models and determine how broadly the platform may apply across solid tumors.
John and Lyle dig into the science behind the platform, why tumor heterogeneity makes cancer so difficult to treat, and how DDCs could eventually make combinations of powerful therapies more practical.
But the episode is just as much about persistence as it is about cancer.
Lyle talks about spending more than 15 years and millions of his own dollars pursuing the technology, why he continued when others might have stopped, and what decades of invention have taught him about failure, focus, humility, and being willing to think differently.
They also discuss a life filled with calculated risk, from building companies from scratch to rafting the Grand Canyon just weeks after breaking his back, and why Lyle believes everything he has done has prepared him for the work he is doing now.
About Lyle Small: Lyle Small is Founder and CEO of Lahjavida Bio and founder of Chromatic Technologies, Inc. (CTI). A Cornell-trained bioengineer with more than 20 patents, he developed the color-changing technology used on Coors Light cans. He has spent more than 15 years and millions of his own dollars advancing Lahjavida’s oncology platform.
About Lahjavida Bio: Lahjavida Bio is a Colorado-based preclinical oncology company developing Dye-Drug Conjugates to deliver therapies more selectively to tumors. Spun out of CTI in 2018, the company is advancing its lead compound, DDC6, toward an investigational new drug filing. It holds four issued U.S. patents, with additional applications pending.
About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm investing in innovative private companies across healthcare, technology, defense, and other emerging industries. Xcellerant offers multiple investment vehicles, including the Jetstream Venture Fund (an interval fund with a $5,000 minimum) and select SPVs, while partnering with founders through capital, strategic guidance, and its broader network.